Cosmo Pharmaceuticals N.V. (SWX:COPN)

Market Cap	840.79M
Revenue (ttm)	250.29M
Net Income (ttm)	125.00M
Shares Out	16.02M
EPS (ttm)	7.61
PE Ratio	6.90
Forward PE	n/a
Dividend	1.93 (3.67%)
Ex-Dividend Date	Jun 4, 2025

Volume	14,818
Average Volume	25,745
Open	53.10
Previous Close	52.50
Day's Range	51.50 - 53.10
52-Week Range	41.60 - 80.60
Beta	1.29
RSI	58.02
Earnings Date	Jul 23, 2025

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delive...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1997
• Employees: 322
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: COPN

Financial Performance

Financial numbers in EUR